GHRP-6 Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: Small early-phase pharmacodynamic studies.

Animal evidence: Preclinical ghrelin-receptor pharmacology, including some of the earliest work defining the ghrelin receptor itself.

Introduction & Mechanism of Action

Ghrelin-receptor agonist studied for growth-hormone release and appetite-stimulation research.

One of the original ghrelin-receptor agonist hexapeptides; known in the literature for a pronounced appetite-stimulating effect alongside GH release, more so than Ipamorelin or GHRP-2.

Receptors/targets: Ghrelin receptor (GHS-R1a)

Areas of Research Interest

• Growth-hormone release research
• Appetite-stimulation studies

Benefits Reported in Research

• Growth-hormone release research
• Appetite-stimulation studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 100–300 mcg

Reported frequency: 2–3× daily, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on GHRP-6 reports administration at 100–300 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Significant appetite increase
• Flushing
• Water retention
• Injection-site reaction

Contraindications

• Active malignancy (theoretical concern)
• Pregnancy

Drug interactions

• Not well characterized in controlled human trials

Safety

• Pronounced appetite stimulation may be undesirable depending on research goal
• Cortisol and prolactin elevation

Known for a pronounced appetite-stimulating effect in the literature; long-term human safety data is limited.

Expected Results & Comparison

GHRP-6 is known for the most pronounced appetite-stimulating effect of the three ghrelin-receptor agonists in this catalog — a relevant distinguishing factor for research where appetite change is or isn't desired, separate from GH-release potency itself.

References

Continue